Intranasal sumatriptan: In adolescents with migraine

被引：7

作者：

Curran M.P. ^{[1
,2
]}

Evans H.C. ^{[1
]}

Wagstaff A.J. ^{[1
]}

机构：

[1] Adis International Limited, Auckland

[2] Adis International Limited, Auckland 1311

来源：

CNS Drugs | 2005年 / 19卷 / 4期

关键词：

Migraine; Sumatriptan; Migraine Attack; Butorphanol; Trigeminal Nucleus Caudalis;

D O I：

10.2165/00023210-200519040-00006

中图分类号：

学科分类号：

摘要：

Sumatriptan, a serotonin 5-HT1B/1D agonist, constricts cranial blood vessels and inhibits neuroinflammatory processes. A single dose of sumatriptan 10mg (approved European dosage) was significantly more effective than placebo in achieving headache relief at 1 hour post-dose in a well designed study. Headache relief occurred in significantly more adolescents administered a single dose of intranasal sumatriptan 20mg (at 1 and 2 hours) and 5mg (at 2 hours) than placebo (pooled data from two studies). Sustained headache relief (1-24 and 2-24 hours) occurred in significantly more recipients of a single dose of intranasal sumatriptan 20mg and 5mg than placebo (pooled data from two studies). Intranasal sumatriptan was generally well tolerated in adolescent migraineurs (in single-episode studies or long term in multiple-episode studies). Taste disturbance occurred more often with intranasal sumatriptan than with placebo. © 2005 Adis Data Information BV. All rights reserved.

引用

页码：335 / 343

页数：8

共 29 条

[21]

Fowler P.A., Lacey L.F., Keene O.N., Et al., Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan, Cephalalgia, 11, SUPPL. 11, pp. 228-229, (1991)

[22]

Vachharajani N.N., Shyu W.C., Nichola P.S., Et al., A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: Importance of the timing of butorphanol administration, Cephalalgia, 22, 4, pp. 282-287, (2002)

[23]

Winner P., Rothner D., Webster C., Et al., Randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in adolescent migraineurs, Neurology, 62, SUPPL. 5, (2004)

[24]

Ahonen K., Hamalainen M.L., Rantala H., Et al., Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial, Neurology, 62, 6, pp. 883-887, (2004)

[25]

Winner P., Rothner A.D., Saper J., Et al., A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents, Pediatrics, 106, 5, pp. 989-997, (2000)

[26]

Winner P., Rothner A.D., Webster C., Et al., Overall efficacy of sumatriptan nasal spray in adolescent migraineurs: Pooled results from US placebo-controlled trials, Headache, 44, 5, pp. 481-482, (2004)

[27]

Rothner A.D., Winner P., Nett R., Et al., One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: Results of a multicenter, open-label study, Clin Ther, 22, 12, pp. 1533-1546, (2000)

[28]

Natarajan S., Jabbour J.T., Webster C.J., Et al., Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine, Headache, 44, pp. 969-977, (2004)

[29]

Woodman R., Glaxo Rolls out Migraine Drug Imigran Nasal Spray for Adolescents in Europe 2003 [Online]

← 1 2 3 →